Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine Tumors
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide on the overall treatment paradigm for patients with neuroendocrine tumors.
The approval gave creditability to the use of somatostatin analogs as antiproliferative agents, Kunz says. Many oncologists have long been using the somatostatin analog octreotide as an antiproliferative agent for the treatment of small bowel neuroendocrine tumors, despite it not having FDA label for that use, Kunz suggests.
As a result of lanreotide (Somatuline Depot) being applied to a larger patient population in the CLARINET study, Kunz says many oncologists are expanding the patient population for which they consider somatostatin analogs as antiproliferative agents.
<<<
